Request Demo
Last update 10 May 2025
SM3321
Last update 10 May 2025
Overview
Basic Info
Drug Type Antibody |
Synonyms SM 3321, SM-3321, SM3321 |
Target |
Action agonists |
Mechanism CD16a agonists(Low affinity immunoglobulin gamma Fc region receptor III-A agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with SM3321NCT06087770
An Open-label, Dose-escalation Phase Ia Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SM3321 in Patients With Locally Advanced or Metastatic Solid Tumors
ChiCTR2300073579
An open-label, dose-escalation, and dose-expansion Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of SM3321 in patients with relapsed/refractory advanced malignancies
100 Clinical Results associated with SM3321
Login to view more data
100 Translational Medicine associated with SM3321
Login to view more data
100 Patents (Medical) associated with SM3321
Login to view more data
100 Deals associated with SM3321
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 07 Dec 2023 | |
| Advanced cancer | Phase 1 | China | 31 Aug 2023 | |
| Myelodysplastic Syndromes | Phase 1 | - | 05 Jun 2023 | |
| Acute Myeloid Leukemia | IND Approval | China | 17 Jan 2023 | |
| Hematologic Neoplasms | IND Application | United States | 14 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free